Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.56 |
| ▸ | MTOR | P42345 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821962 | 0.83 | CYP1A2 (0.47) | PTK2PRKDCCYP1A2CYP2C9KDM4E | |
| SCHEMBL2276716 | 0.79 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGMTORPOLB | |
| SCHEMBL25724448 | 0.79 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGMTORPOLB | |
| SCHEMBL27272553 | 0.79 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGMTORPOLB | |
| SCHEMBL14843260 | 0.79 | PTK2 (1.00) | PTK2PIK3CAPOLBPRKDCCYP1A2 | |
| SCHEMBL25719191 | 0.78 | ATR (0.51) | PTK2MTOR | |
| SCHEMBL31705145 | 0.76 | PTK2 (0.63) | PTK2PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL25719397 | 0.76 | PTK2 (0.63) | PTK2PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL25277910 | 0.76 | PIK3CD (0.61) | PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL30456000 | 0.76 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-2396322-B9 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-2396322-B1 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-02-03 | — | — | EP | disclosed |
| EP-2563788-B1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES | KARUS THERAPEUTICS LTD (GB) | 2015-08-05 | — | — | EP | disclosed |
| US-8609666-B2 | 2-morpholino-pyrido[3,2-D]pyrimidines | MERCK SERONO SA (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2396322-A1 | 2-MORPHOLINO-PYRIDOÝ3,2-D¨PYRIMIDINES | Merck Serono SA (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2011-12-01 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2344490-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES ACTIVE ON PI3K | Merck Serono S.A. (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010091996-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CB | PTK2 1228/4885PIK3CA 1/4885PIK3CD 2/4885 |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | PTK2 953/4885PIK3CA 1/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.